Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21177249
Murata H, et al. (2011) A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK/PINK1: activation of AKT via mTORC2. J Biol Chem 286, 7182-9 21177249
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) no change compared to control
EGF increase
AG1478 EGF inhibit treatment-induced increase
PI-103 EGF inhibit treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
Akt_inhibitor_VIII EGF inhibit treatment-induced increase

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo immunoassay, phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma, prostate cancer
Relevant cell lines - cell types - tissues:  DU 145 (prostate cell), PC3 (prostate cell), SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
MG132 increase
MG132 PINK1 (human) increase PINK siRNA inhibits
EGF increase
AG1478 EGF inhibit treatment-induced increase
PINK1 (human) increase siRNA decrease
AG1478 PINK1 (human) no effect upon treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
wortmannin PINK1 (human) no effect upon treatment-induced increase
rapamycin PINK1 (human) inhibit treatment-induced increase
RICTOR (human) increase siRNA decrease
PI-103 EGF inhibit treatment-induced increase
PI-103 PINK1 (human) no effect upon treatment-induced increase
Akt_inhibitor_VIII PINK1 (human) inhibit treatment-induced increase
Akt_inhibitor_VIII EGF inhibit treatment-induced increase
Downstream Regulation
Effect of modification (function):  phosphorylation
Effect of modification (process):  apoptosis, inhibited, cell motility, induced

S99-p - BAD (human)
Modsite: PFrGrsRsAPPNLWA SwissProt Entrez-Gene
Orthologous residues
BAD (human): S99‑p, BAD (mouse): S136‑p, BAD (rat): S137‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
AG1478 EGF inhibit treatment-induced increase
PINK1 (human) increase
AG1478 PINK1 (human) no effect upon treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
wortmannin PINK1 (human) no effect upon treatment-induced increase
PI-103 EGF inhibit treatment-induced increase
PI-103 PINK1 (human) no effect upon treatment-induced increase
Akt_inhibitor_VIII PINK1 (human) inhibit treatment-induced increase
Akt_inhibitor_VIII EGF inhibit treatment-induced increase

T24-p - FOXO1A (human)
Modsite: LPRPRSCtWPLPRPE SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): T24‑p, FOXO1A (mouse): T24‑p, FOXO1A (rat): T24‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
AG1478 EGF inhibit treatment-induced increase
PINK1 (human) increase
AG1478 PINK1 (human) no effect upon treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
wortmannin PINK1 (human) no effect upon treatment-induced increase
PI-103 EGF inhibit treatment-induced increase
PI-103 PINK1 (human) no effect upon treatment-induced increase
Akt_inhibitor_VIII PINK1 (human) inhibit treatment-induced increase
Akt_inhibitor_VIII EGF inhibit treatment-induced increase

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) no change compared to control
EGF increase
AG1478 EGF inhibit treatment-induced increase
PI-103 EGF inhibit treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
Akt_inhibitor_VIII EGF inhibit treatment-induced increase

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) increase
rapamycin PINK1 (human) inhibit treatment-induced increase

S380-p - PTEN (human)
Modsite: EPDHyRYsDttDsDP SwissProt Entrez-Gene
Orthologous residues
PTEN (human): S380‑p, PTEN iso2 (human): S553‑p, PTEN (mouse): S380‑p, PTEN (rat): S380‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) increase
EGF increase

T382-p - PTEN (human)
Modsite: DHyRYsDttDsDPEN SwissProt Entrez-Gene
Orthologous residues
PTEN (human): T382‑p, PTEN iso2 (human): T555‑p, PTEN (mouse): T382‑p, PTEN (rat): T382‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) increase
EGF increase

T383-p - PTEN (human)
Modsite: HyRYsDttDsDPENE SwissProt Entrez-Gene
Orthologous residues
PTEN (human): T383‑p, PTEN iso2 (human): T556‑p, PTEN (mouse): T383‑p, PTEN (rat): T383‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) increase
EGF increase

T1462-p - TSC2 (human)
Modsite: GLRPRGytISDsAPs SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  neuroblastoma
Relevant cell lines - cell types - tissues:  SH-SY5Y (neural crest)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PINK1 (human) no change compared to control
EGF increase
AG1478 EGF inhibit treatment-induced increase
PI-103 EGF inhibit treatment-induced increase
wortmannin EGF inhibit treatment-induced increase
Akt_inhibitor_VIII EGF inhibit treatment-induced increase